流行SARS-CoV-2變異株產品大合集
日期：2021-08-25 16:14:47
2019年底爆發的COVID19疫情仍在全球肆虐。SARS-CoV-2，作為這種流行病的起因，突變速度令人瞠目結舌。SARS-CoV-2僅用了一年多的時間，從 Alpha 發展到 Lambda，讓WHO用了將近 1/2 的希臘字母來為其變異株命名。2020年12月末，在英國發現SARS-CoV-2變異株Alpha，至此，英國疫情失控。緊接著，在南非發現了變異株Beta，在印度發現了變異株Delta，在秘魯發現了變異株Lambda。
針對全球SARS-CoV-2的主要變種，華美生物可提供多種標簽的優質突變抗原。絕大多數突變抗原已驗證生物活性。
如果您對其他突變株感興趣，可點擊頁面右側的在線咨詢聯系我們定制。➤➤➤
>>SARS-CoV-2 Lambda | C.37 （南美突變株）
| Target | Product Name | Code | Source | Mutation | Tag Info |
|---|---|---|---|---|---|
| N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K,G204R) (Active) | CSB-EP3325GMY(M12) | E.coli | R203K, G204R | N-terminal 6xHis-tagged |
>>SARS-CoV-2 Delta | B.1.617.2 （印度突變株）
| Target | Product Name | Code | Source | Mutation | Tag Info |
|---|---|---|---|---|---|
| N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (D63G,R203M,D377Y) (Active) | CSB-EP3325GMY(M14) | E.coli | D63G, R203M, D377Y | N-terminal 6xHis-tagged |
>>SARS-CoV-2 Kappa | B.1.617.1 （印度突變株）
| Target | Product Name | Code | Source | Mutation | Tag Info |
|---|---|---|---|---|---|
| N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203M,D377Y) (Active) | CSB-EP3325GMY(M13) | E.coli | R203M, D377Y | N-terminal 6xHis-tagged |
>>SARS-CoV-2 Alpha | B.1.1.7 （英國突變株）
| Target | Product Name | Code | Source | Mutation | Tag Info |
|---|---|---|---|---|---|
| N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (D3L,R203K,G204R,S235F) (Active) | CSB-EP3325GMY(M1) | E.coli | D3L, R203K, G204R, S235F | N-terminal 6xHis-tagged |
| N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (R203K,G204R) (Active) | CSB-EP3325GMY(M12) | E.coli | R203K, G204R | N-terminal 6xHis-tagged |
| S1 | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G),partial (Active) | CSB-MP3324GMY(M1) | Mammalian cell | D614G | C-terminal 10xHis-tagged |
| S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6) | Mammalian cell | N501Y | C-terminal 10xHis-tagged |
| S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6)k2 | Mammalian cell | N501Y | C-terminal 6xHis-mFC-tagged |
>>SARS-CoV-2 Beta | B.1.351 （南非突變株）
>>SARS-CoV-2 Gamma | P.1 （巴西突變株）
| Target | Product Name | Code | Source | Mutation | Tag Info |
|---|---|---|---|---|---|
| N | Recombinant Human Novel Coronavirus Nucleoprotein (N) (P80R) (Active) | CSB-EP3325GMY(M3) | E.coli | P80R | N-terminal 6xHis-tagged |
| S1 | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (D614G),partial (Active) | CSB-MP3324GMY(M1) | Mammalian cell | D614G | C-terminal 10xHis-tagged |
| S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6) | Mammalian cell | N501Y | C-terminal 10xHis-tagged |
| S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein (S) (N501Y),partial (Active) | CSB-MP3324GMY1(M6)k2 | Mammalian cell | N501Y | C-terminal 6xHis-mFC-tagged |
| S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein(S)(E484K),partial | CSB-MP3324GMY1(M8) | Mammalian cell | E484K | C-terminal 10xHis-tagged |
| S1-RBD | Recombinant Human Novel Coronavirus Spike glycoprotein(S) (E484K), partial (Active) | CSB-MP3324GMY1(M8)h8 | Mammalian cell | E484K | C-terminal mFC-tagged |
>>其他SARS-CoV-2 突變株
>>部分驗證數據
● Recombinant Human Novel Coronavirus Nucleoprotein (N)(R203K,G204R) (Active) (CSB-EP3325GMY(M12))
Its purity is greater than 96% as determined by SDS-PAGE.
Its binding ability measured by functional ELISA with N Mouse Monoclonal Antibody at 2 μg/ml, of which EC50 is 6.775-13.04 ng/ml.
Its binding ability measured by functional ELISA with N Recombinant Antibody at 2 μg/ml, of which EC50 is 4.664-8.256 ng/ml.
Its purity is greater than 85.7% as determined by SDS-PAGE.
Its binding ability measured by functional ELISA with N Mouse Monoclonal Antibody at 2 μg/ml, of which EC50 is 3.834 - 5.294 ng/ml.
Its binding ability measured by functional ELISA with N Recombinant Antibody at 2 μg/ml, of which EC50 is 1.304 - 1.875 ng/ml ng/ml.
Its purity is greater than 90% as determined by SDS-PAGE.
Its binding ability measured by functional ELISA with human ACE2 at 2 μg/ml, the EC50 is 6.597-8.187 ng/ml.
Its binding ability measured by functional ELISA with Biotin-S Antibody at 2 μg/ml, the EC50 is 118.7 ng/ml.
